Amgen, Cedars-Sinai team up in value-based care effort

Los Angeles-based Cedars-Sinai Medical Center tapped biotechnology company Amgen in a new, three-year partnership tasked with researching ways to improve treatment quality for oncology, cardiovascular disease, osteoporosis and migraine.

Under the agreement, Amgen and Cedars-Sinai will work on projects that could result in better clinical outcomes, experience and patient satisfaction. Initially, the partnership proposed studying cancer therapies.

The collaboration will also combine Amgen's population health expertise with Cedars-Sinai's use of the EHR to identify patients in need of treatment as a way of finding more patients at-risk of developing chronic conditions.

"This synergistic partnership between two major health care entities is devoted to furthering discovery in large populations burdened with chronic diseases," said Shlomo Melmed, MD, executive vice president and dean of faculty at Cedars-Sinai. "We are excited to work with Amgen to help improve patient outcomes by expanding our translational and population research programs in precision medicine, care pathway redesign, diagnostic technologies and further harnessing the strength of electronic medical records."

Amgen is currently involved in more than 75 value-based projects, spanning numerous types of agreements, such as risk sharing and outcomes-based contracts.

More articles on population health:

From program to business model: Using population health management to drive value-based care
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Achieving interoperability for better patient care

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 
 

Top 40 Articles from the Past 6 Months